Alemtuzumab induction in renal transplantation: A meta-analysis and systemic review

Transplant Immunology

Volumn 27, Issue 2-3, 2012, Pages 63-68

  Zhang, Xin ^a   Huang, Hejing ^a   Han, Shu ^a   Fu, Shangxi ^a   Wang, Liming ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alemtuzumab; Meta analysis; Randomized controlled trials; Renal transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; DELAYED GRAFT FUNCTION; DRUG EFFICACY; DRUG SAFETY; GRAFT FAILURE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECIPIENT; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTILYMPHOCYTE SERUM; GLYCOPROTEINS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RABBITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84868373684     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.08.006     Document Type: Review

References (23)

1. Ciancio G., Burke G.W., Miller J. Induction therapy in renal transplantation: an overview of current developments. Drugs 2007, 67:2667-2680.
2. Padiyar A., Augustine J.J., Hricik D.E. Induction antibody therapy in kidney transplantation. Am J Kidney Dis 2009, 54:935-944.
3. Meier-Kriesche H.U., Arndorfer J.A., Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002, 13:769-772.
4. Webster A.C., Ruster L.P., McGee R., Matheson S.L., Higgins G.Y., Willis N.S., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010, CD003897.
5. Brennan D.C., Daller J.A., Lake K.D., Cibrik D., Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006, 355:1967-1977.
6. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 2005, 19:39-46.
7. Bloom D.D., Hu H., Fechner J.H., Knechtle S.J. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006, 81:81-87.
8. Calne R., Moffatt S.D., Friend P.J., Jamieson N.V., Bradley J.A., Hale G., et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999, 68:1613-1616.
9. Weaver T.A., Kirk A.D. Alemtuzumab. Transplantation 2007, 84:1545-1547.
10. Hanaway M.J., Woodle E.S., Mulgaonkar S., Peddi V.R., Kaufman D.B., First M.R., et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011, 364:1909-1919.
11. Ciancio G., Burke G.W., Gaynor J.J., Carreno M.R., Cirocco R.E., Mathew J.M., et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005, 80:457-465.
12. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
13. Farney A., Sundberg A., Moore P., Hartmann E., Rogers J., Doares W., et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008, 22:41-49.
14. Lu T.M., Yang S.L., Wu W.Z., Tan J.M. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Chin Med J (Engl) 2011, 124:664-668.
15. Chan K., Taube D., Roufosse C., Cook T., Brookes P., Goodall D., et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy-an open label, randomized trial. Transplantation 2011, 92:774-780.
16. Farney A.C., Doares W., Rogers J., Singh R., Hartmann E., Hart L., et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009, 88:810-819.
17. Ciancio G., Burke G.W., Gaynor J.J., Roth D., Kupin W., Rosen A., et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008, 22:200-210.
18. Thomas P.G., Woodside K.J., Lappin J.A., Vaidya S., Rajaraman S., Gugliuzza K.K. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007, 83:1509-1512.
19. Woodle E.S., Alloway R.R., Buell J.F., Alexander J.W., Munda R., Roy-Chaudhury P., et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005, 5:2740-2744.
20. Liu Y., Zhou P., Han M., Xue C.B., Hu X.P., Li C. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transplant Proc 2010, 42:1667-1670.
21. Wagner S.J., Brennan D.C. Induction therapy in renal transplant recipients: how convincing is the current evidence?. Drugs 2012, 72:671-683.
22. Kim H.C., Hwang E.A., Kang M.J., Han S.Y., Park S.B., Park K.K. BK virus infection in kidney transplant recipients. Transplant Proc 2004, 36:2113-2115.
23. Quiroga I., McShane P., Koo D.D., Gray D., Friend P.J., Fuggle S., et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006, 21:1689-1696.